Washout Rate of Tc-99m Mibi in Bone and Soft-Tissue Sarcomas

Neoadjuvant therapy is employed before the primary treatment of sarcomas. It is not uncommon that it fails due to multi-drug resistance gene causing unnecessary delays in surgery. Tc-99m MIBI, a radiopharmaceutical, is taken-up in these tumours. Being substrate of P-glycoprotein (Pgp), its washout from the malignant tissue may predict the response of sarcoma to neoadjuvant therapy. This book presents the author’s experience of in-vivo quantitative estimation of the washout rates of Tc-99m MIBI from nuclear medicine scans of various bone and soft-tissue sarcomas. These rates were then assessed for their ability to predict the effectiveness of neoadjuvant therapy initiated afterwards.

Dr Muhammad Sohaib is a nuclear medicine physician with medical graduation from Quaid-e-Azam Medical College, masters from PIEAS and clinical fellowship from CPSP. Currently he is a faculty member in PIEAS working as an academician, researcher and clinician. He has several research articles to his credit published in high impact factor journals.